8-K: Certara Reports Q2 2026 Results, Reaffirms Guidance

Certara announced its second quarter 2026 financial results, reporting modest revenue growth, a net loss, and a decrease in Adjusted EBITDA, while reaffirming its full-year revenue guidance and authorizing an additional $50 million share repurchase program.

Summary

• Certara reported second quarter 2026 revenue of $93.3 million, a 1% increase year-over-year.
• Software revenue grew 4% to $48.8 million, while Services revenue decreased 3% to $44.5 million.
• The company reported a net loss of $6.1 million for the quarter, compared to a net income of $1.5 million in Q2 2025.
• Adjusted EBITDA was $26.2 million, a 3% decrease from $27.0 million in the prior year's second quarter.
• Certara reaffirmed its full-year 2026 revenue guidance of 0% to 4% growth on a comparable continuing operations basis.
• The company completed a $100 million share repurchase program and its Board authorized an additional $50 million.
• Julien Perrier was appointed Chief Commercial Officer, effective August 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with modest revenue growth offset by a net loss and decreased Adjusted EBITDA, but with a reaffirmed revenue outlook and a new share repurchase authorization.

Positives

• Revenue increased by 1% to $93.3 million in the second quarter of 2026.
• Software revenue showed a healthy 4% growth, reaching $48.8 million.
• Software bookings increased by 9% year-over-year, indicating future software revenue strength.
• The company reaffirmed its full-year 2026 revenue growth guidance of 0% to 4%.
• An additional $50 million share repurchase program was authorized, demonstrating confidence in the business.
• The divestiture of the Regulatory and Medical Writing business was completed, streamlining operations.

Negatives

• Net loss for the quarter was $6.1 million, a significant shift from a net income of $1.5 million in Q2 2025.
• Adjusted EBITDA decreased by 3% to $26.2 million compared to $27.0 million in Q2 2025.
• Services revenue experienced a 3% decrease, falling to $44.5 million.
• Services bookings decreased by 6% year-over-year.
• Total operating expenses increased by $7.9 million, primarily due to contingent consideration adjustments and reorganization costs.

Risks

• The company faces risks related to the acceptance of model-informed biopharmaceutical discovery and development.
• Competition within the market and changes in government regulation for the biopharmaceutical industry are potential challenges.
• Trends in research and development spending and operational disruptions at regulatory agencies like the FDA could impact the business.
• Risks associated with the implementation, use, and development of artificial intelligence and machine learning in products and services.
• Potential for existing customers to not renew software licenses or to terminate contracts or reduce scope of work.
• Risks related to cybersecurity, data breaches, and compliance with privacy laws.

Future Outlook

Certara reaffirms its full-year 2026 revenue growth guidance of 0% to 4% on a comparable continuing operations basis, expecting revenue between $367 million and $382 million. The company also projects a full-year adjusted EBITDA margin of 29% to 31% and adjusted diluted earnings per share in the range of $0.31 to $0.36.

Management Comments

• "This second quarter was about continuing to execute on our commitments. Overall, we are pleased with our ongoing progress transforming Certara into a company we believe can deliver sustainable double-digit growth," said Jon Resnick, Chief Executive Officer.
• "Our second quarter results were in line with our expectations, and we remain focused on executing against our full-year plan," said Faiz Mohammed, Interim Chief Financial Officer.
• "We continue to expect full-year revenue growth of 0% to 4% on a comparable continuing operations basis, supported by continued strength in software and improving services performance as we move through the second half of the year."

Industry Context

StockSavvy.ai notes that Certara's focus on model-informed drug development places it within a growing segment of the life sciences industry that leverages data and simulation to accelerate therapeutic innovation. The company's strategic reorganization into two business units (MID3 and ACE) and the divestiture of its medical writing business suggest a move towards greater specialization and efficiency, aligning with industry trends of streamlining operations to focus on core competencies.

Management Changes

Stakeholder Impact

• Shareholders: The reaffirmation of revenue guidance and authorization of an additional $50 million share repurchase program may be viewed positively, while the net loss and decreased Adjusted EBITDA could be a concern.
• Employees: A reduction in force impacting approximately 5% of the global employee base was executed, aimed at operational excellence and cost savings.
• Customers: The appointment of a new Chief Commercial Officer and reorganization into two business units are intended to deepen customer engagement and ensure products/services deliver clear value.

Next Steps

• Focus on customer impact and speed of execution in the second half of the year.
• Continue executing against the full-year plan.
• Improve services performance as the second half of the year progresses.

Key Dates

Recommendation

The company is showing modest revenue growth and reaffirming guidance, which is positive. However, the shift to a net loss and decrease in Adjusted EBITDA, coupled with a significant increase in operating expenses, warrants a cautious approach. The strategic restructuring and new leadership are promising, but their impact on future profitability needs to be observed. The share repurchase program provides some support, but the overall financial performance indicates a 'hold' position until clearer signs of sustained profitability and growth emerge.

Keywords

biosimulation, drug development, software revenue, services revenue, financial results, share repurchase, EBITDA, revenue guidance